| Literature DB >> 24828261 |
Jessica L Buxton1, Matthew Suderman2, Jane J Pappas3, Nada Borghol4, Wendy McArdle5, Alexandra I F Blakemore6, Clyde Hertzman7, Christine Power8, Moshe Szyf9, Marcus Pembrey8.
Abstract
In humans, leukocyte telomere length (LTL) is positively correlated with lifespan, and shorter LTL is associated with increased risk of age-related disease. In this study we tested for association between telomere length and methylated cytosine levels. Measurements of mean telomere length and DNA methylation at >450,000 CpG sites were obtained for both blood (N = 24) and EBV-transformed cell-line (N = 36) DNA samples from men aged 44-45 years. We identified 65 gene promoters enriched for CpG sites at which methylation levels are associated with leukocyte telomere length, and 36 gene promoters enriched for CpG sites at which methylation levels are associated with telomere length in DNA from EBV-transformed cell-lines. We observed significant enrichment of positively associated methylated CpG sites in subtelomeric loci (within 4 Mb of the telomere) (P < 0.01), and also at loci in imprinted regions (P < 0.001). Our results pave the way for further investigations to help elucidate the relationships between telomere length, DNA methylation and gene expression in health and disease.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24828261 PMCID: PMC4344300 DOI: 10.1038/srep04954
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Scatterplot showing lack of correlation between telomere measurements in whole blood and EBV cell-line DNA taken from the same individual (N = 22) (Spearman ρ = −0.3, P = 0.18).
Identification of gene promoters enriched for sites at which methylation levels are associated with telomere length: summary data (SD = standard deviation, TSS = transcription start site)
| Blood (N = 24) | Cell-line (N = 36) | |
|---|---|---|
| Mean telomere length, T/S ratio (SD) | 1.00 (0.29) | 1.26 (0.45) |
| Genes with TSS near associated CpG sites | 65 | 36 |
| Imprinted genes with associated CpG sites | 12 | 3 |
| Genes near telomeres with associated CpG sites | 12 | 8 |
| Associated CpG sites (all) | 464 | 125 |
| Associated CpG sites (positive) | 364 (78%) | 94 (75%) |
| Associated CpG sites (negative) | 100 (22%) | 31 (25%) |
Figure 2Heatmaps showing M-value variation for CpG sites (rows) across study participants (columns), in A) whole blood and B) cell-line DNA samples.
Samples and CpG sites clustered using the Ward algorithm with Pearson's correlation as the distance metric. Relatively lower methylation levels are shown in green and higher methylation levels in red. The key for the telomere length of each sample in both heatmaps is given on the top right of the figure.
Figure 3Scatterplots showing examples of positive associations between telomere length (T/S ratio, X-axis) in blood DNA and on the Y-axis, methylation levels at two loci located in subtelomeric regions: A) cg21024264, located 193 kb from chr10 qter within CYP2E1 gene promoter region and B) cg25020933, located 369 kb from chr11 pter within B4GALNT4 gene promoter region.
Each point represents the mean T/S ratio of duplicate measurements for an individual DNA sample.
Results of Ingenuity pathway and network analysis for genes with promoters enriched for CpG sites at which methylation levels are associated with telomere length in either blood DNA (65 genes) or cell-line DNA (36 genes). Details of the disorders and gene names for the analysis of blood DNA are given in Table S1
| BLOOD DNA | CELL LINE DNA | ||||
|---|---|---|---|---|---|
| Developmental Disorders | 9.59E-05 - 4.39E-02 | 13 | Developmental Disorders | 1.28E-03 - 4.40E-02 | 4 |
| Endocrine System Disorders | 9.59E-05 - 4.39E-02 | 18 | Endocrine System Disorders | 1.28E-03 - 3.91E-02 | 3 |
| Gastrointestinal Disease | 9.59E-05 - 4.77E-02 | 15 | Hereditary Disorders | 1.28E-03 - 4.77E-02 | 4 |
| Hereditary Disorders | 9.59E-05 - 4.39E-02 | 15 | Infectious Disease | 1.28E-03 - 4.41E-02 | 6 |
| Reproductive System Disease | 9.59E-05 - 4.22E-02 | 14 | Metabolic Disease | 1.28E-03 - 3.91E-02 | 2 |
| Gene Expression | 1.86E-06 - 4.77E-02 | 19 | Cell Cycle | 1.28E-03 - 3.66E-02 | 2 |
| Cellular Development | 1.39E-04 - 4.77E-02 | 16 | Cellular Compromise | 1.28E-03 - 1.28E-03 | 1 |
| Cell Morphology | 6.62E-04 - 3.68E-02 | 12 | Cellular Development | 1.28E-03 - 4.52E-02 | 8 |
| Cell-To-Cell Signaling and Interaction | 1.07E-03 - 3.78E-02 | 10 | Cellular Movement | 1.28E-03 - 3.04E-02 | 4 |
| Drug Metabolism | 1.07E-03 - 3.78E-02 | 3 | Energy Production | 1.28E-03 - 1.02E-02 | 2 |
| Connective Tissue Dev't and Function | 2.14E-05 - 4.03E-02 | 7 | Cardiovascular System Development and Function | 1.28E-03 - 4.15E-02 | 2 |
| Embryonic Development | 2.14E-05 - 4.81E-02 | 15 | Embryonic Development | 1.28E-03 - 4.52E-02 | 3 |
| Organ Development | 2.14E-05 - 4.52E-02 | 14 | Nervous System Development and Function | 1.28E-03 - 4.28E-02 | 3 |
| Organ Morphology | 2.14E-05 - 4.52E-02 | 12 | Organ Development | 1.28E-03 - 4.52E-02 | 3 |
| Organismal Development | 2.14E-05 - 4.81E-02 | 13 | Organ Morphology | 1.28E-03 - 4.89E-02 | 6 |
| Dopamine-DARPP32 Feedback in cAMP Signaling | 8.40E-03 | 3 of 186 | B Cell Development | 7.61E-04 | 2 of 33 |
| Lymphotoxin b Receptor Signaling | 8.46E-03 | 2 of 61 | Nur77 Signaling in T Lymphocytes | 2.24E-03 | 2 of 63 |
| Prod'n of NO and ROS in Macrophages | 1.08E-02 | 3 of 211 | IL-4 Signaling | 4.01E-03 | 2 of 79 |
| Pregnenolone Biosynthesis | 1.53E-02 | 1 of 13 | SAPK/JNK Signaling | 6.53E-03 | 2 of 103 |
| Dopamine Receptor Signaling | 1.63E-02 | 2 of 95 | iCOS-iCOSL Signaling in T Helper Cells | 8.21E-03 | 2 of 123 |
Characteristics of the 38 male study participants
| Age (y) | n | ||
|---|---|---|---|
| Childhood manual social class n (%) | 0 | 19 (50.0) | 38 |
| Adulthood manual social class, n (%) | 42 | 20 (52.6) | 38 |
| Education level – below O level, n (%) | 42 | 9 (23.7) | 38 |
| Smoker, n (%) | 42 | 10 (27.0) | 37 |
| Alcohol drinks daily, n (%) | 42 | 9 (24.3) | 37 |
| Birth weight, g, mean ± SD | birth | 3522 (590) | 37 |
| Height, m, mean ± SD | 7 | 1.23 (0.07) | 35 |
| Height, m, mean ± SD | 42 | 1.77 (0.08) | 37 |
| Body mass index, kg/m2, mean ± SD | 45 | 27.5 (4.07) | 38 |
| Waist circumference, cm, mean ± SD | 45 | 99.6 (10.5) | 38 |
| Systolic blood pressure, mmHg, mean ± SD | 45 | 134.4 (18.3) | 38 |
| Diastolic blood pressure, mmHg, mean ± SD | 45 | 84.5 (11.6) | 38 |
| FEV1 | 45 | 3.82 (0.64) | 34 |
*FEV1 = one-second forced expiratory volume; best test of three spirometry readings.